HK1210698A1 - Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions - Google Patents

Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Info

Publication number
HK1210698A1
HK1210698A1 HK15111435.3A HK15111435A HK1210698A1 HK 1210698 A1 HK1210698 A1 HK 1210698A1 HK 15111435 A HK15111435 A HK 15111435A HK 1210698 A1 HK1210698 A1 HK 1210698A1
Authority
HK
Hong Kong
Prior art keywords
apoaequorin
methods
multiple sclerosis
containing compositions
alleviating symptoms
Prior art date
Application number
HK15111435.3A
Other languages
English (en)
Chinese (zh)
Inventor
‧安德伍德
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of HK1210698A1 publication Critical patent/HK1210698A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
HK15111435.3A 2012-09-27 2015-11-19 Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions HK1210698A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706615P 2012-09-27 2012-09-27
PCT/US2013/062268 WO2014052807A1 (en) 2012-09-27 2013-09-27 Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Publications (1)

Publication Number Publication Date
HK1210698A1 true HK1210698A1 (en) 2016-05-06

Family

ID=50389004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111435.3A HK1210698A1 (en) 2012-09-27 2015-11-19 Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions

Country Status (24)

Country Link
US (1) US20150246101A1 (pt)
EP (1) EP2900253B1 (pt)
JP (1) JP6607782B2 (pt)
KR (1) KR102195761B1 (pt)
CN (1) CN104684566A (pt)
AU (1) AU2013323288B2 (pt)
BR (1) BR112015006755A2 (pt)
CA (1) CA2886097C (pt)
CY (1) CY1121216T1 (pt)
DK (1) DK2900253T3 (pt)
ES (1) ES2710937T3 (pt)
HK (1) HK1210698A1 (pt)
HR (1) HRP20190182T1 (pt)
HU (1) HUE041492T2 (pt)
IL (1) IL237751B (pt)
LT (1) LT2900253T (pt)
MX (1) MX369389B (pt)
PL (1) PL2900253T3 (pt)
PT (1) PT2900253T (pt)
SG (1) SG11201502418VA (pt)
SI (1) SI2900253T1 (pt)
TR (1) TR201818988T4 (pt)
WO (1) WO2014052807A1 (pt)
ZA (1) ZA201502849B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40959A (fr) * 2014-11-11 2017-09-19 Quincy Bioscience Llc Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale
KR102571660B1 (ko) * 2016-09-23 2023-08-25 퀸시 바이오사이언스 엘엘씨 아포에쿼린 및 비타민 d 함유 조성물 및 이의 사용 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507269B2 (en) * 2007-05-24 2013-08-13 Calcimedica, Inc. Calcium channel proteins and uses thereof
CA2717322C (en) * 2008-03-11 2017-07-11 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
EP2323482A4 (en) * 2008-08-06 2011-08-17 Merck & Co Inc SUBSTITUTED DIHYDROISOCHINOLINONE AND ISOCHINOLINDION DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
WO2012022740A1 (en) * 2010-08-18 2012-02-23 Merck Serono S.A. Combination treatment of multiple sclerosis

Also Published As

Publication number Publication date
PT2900253T (pt) 2019-02-25
PL2900253T3 (pl) 2019-04-30
US20150246101A1 (en) 2015-09-03
AU2013323288B2 (en) 2017-12-07
LT2900253T (lt) 2019-03-25
TR201818988T4 (tr) 2019-01-21
JP6607782B2 (ja) 2019-11-20
KR102195761B1 (ko) 2020-12-28
IL237751B (en) 2020-10-29
SG11201502418VA (en) 2015-04-29
EP2900253A1 (en) 2015-08-05
MX2015003879A (es) 2015-07-17
EP2900253A4 (en) 2016-06-15
CA2886097C (en) 2020-07-14
CA2886097A1 (en) 2014-04-03
WO2014052807A1 (en) 2014-04-03
AU2013323288A1 (en) 2015-05-07
HUE041492T2 (hu) 2019-05-28
JP2015532288A (ja) 2015-11-09
ZA201502849B (en) 2016-07-27
EP2900253B1 (en) 2018-11-14
CN104684566A (zh) 2015-06-03
SI2900253T1 (sl) 2019-03-29
KR20150060954A (ko) 2015-06-03
HRP20190182T1 (hr) 2019-03-22
CY1121216T1 (el) 2020-05-29
BR112015006755A2 (pt) 2017-07-04
MX369389B (es) 2019-11-07
DK2900253T3 (en) 2019-02-18
ES2710937T3 (es) 2019-04-29
IL237751A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
EP2724229A4 (en) SERVICE FOR ADDING A FUNCTIONALITY TO APPLICATIONS
EP2780281A4 (en) GRAPHENE COMPOSITIONS
HK1205947A1 (en) Uses of casein compositions
HK1213912A1 (zh) 用於治療多發性硬化及相關病症的方法和組合物
HRP20160719T1 (hr) Sastav plazme bogate trombocitima
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
EP2763756A4 (en) BROMOFLUOROCARBON COMPOSITIONS
EP2863924A4 (en) METHOD AND COMPOSITION FOR RELIEVING TUMOR SYMPTOMS
EP2702100A4 (en) INSULATION COMPOSITIONS
EP2768481A4 (en) COMPOSITIONS TO REDUCE SIDE EFFECTS
HRP20190182T1 (hr) Postupci za ublažavanje simptoma multiple skleroze na temelju sastava koji sadrže apoaekvorin
GB201103942D0 (en) Compositions
IL234494B (en) Composition for the treatment of menopausal symptoms
ZA201406203B (en) Adjuvant compositions
GB201104849D0 (en) Compositions
IL239623A0 (en) Methods and preparations for administering oxybutynin
HK1212206A1 (en) Compositions for immunotherapy
EP2917733A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS
GB201104200D0 (en) Compositions
GB201104202D0 (en) Compositions
GB201103941D0 (en) Compositions
GB201103943D0 (en) Compositions